

~~This Page Is Inserted by IFW Operations
and is not a part of the Official Record~~

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

XCS Service v1.00
 con .cas
 9351006 COM

Welcome to STN International! Enter x:
 Welcome to STN International! Enter x:x
 LOGINID:ssspta1800mxz
 PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Dec 10 STN Seminar Schedule - N. America
 NEWS 2 Sep 21 MAC & DOS STN Express Users
 NEWS 3 Aug 4 Macintosh STN Express Users of C(O)CH3 Shortcut
 NEWS 4 Dec 2 CAPREVIEWS TO BE DISCONTINUED AFTER DECEMBER 29, 1996
 NEWS 5 Dec 2 SET PLURALS Command for Precision Searching
 NEWS 6 Dec 2 DUPLICATE and SORT L-Numbers Now Searchable
 NEWS 7 Dec 2 New SET AUDIT Command
 NEWS 8 Dec 2 New FOCUS Command and a Special December Offer to
 Help You FOCUS!
 NEWS 9 Dec 11 Now Even More Convenient, Crossover from DPCI to DWPI
 NEWS 10 Dec 11 DJSMDS/DJSMONLINE Now Include 1995 Data
 NEWS 11 Dec 18 AGRICOLA Now On STN
 NEWS 12 Dec 18 New Legal Status Data Added to IFIRXA
 NEWS 13 Dec 18 Free Connect Hour in TULSA/TULSA2 in January
 NEWS 14 Dec 20 FhgPUBLICA No Longer Available as of January 1, 1997
 NEWS 15 Dec 23 New and Revised CA Indexing Terms (1997)
 NEWS 16 Dec 23 1997 STN Prices Available in HELP PRICE NEXT

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

* * * * * STN Columbus * * * * *

*FHGPUBLICA - Publications of the Fraunhofer-Society 1982 - present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 14:40:20 ON 02 JAN 97

FILE 'SCISEARCH' ENTERED AT 15:17:26 ON 02 JAN 97

COPYRIGHT (C) 1997 Institute for Scientific Information (ISI) (R)

=> d 110 bib ab 5 17 25 36 38

L10 ANSWER 5 OF 45 CAPLUS COPYRIGHT 1997 ACS

AN 1995:403077 CAPLUS

DN 122:169735

TI Problems of delivery of monoclonal antibodies: Pharmaceutical and pharmacokinetic solutions

AU Reilly, Raymond M.; Sandhu, Jasbir; Alvarez-Diez, Teresa M.; Gallinger, Steven; Kirsh, Joel; Stern, Hartley

CS Faculty Pharmacy, University Toronto, Toronto, ON, Can.

SO Clin. Pharmacokinet. (1995), 28(2), 126-42

CODEN: CPKNDH; ISSN: 0312-5963

DT Journal; General Review

LA English

AB A review with 131 refs. Monoclonal antibodies to tumor -assocd. antigens have great theor. potential for the specific targeting of radioactivity and antineoplastic agents to tumors. The clin. success of monoclonal antibody-based cancer diagnosis and therapy depends, however, on solving a no. of pharmacokinetic delivery problems. These include: (i) slow elimination of monoclonal antibodies from the blood and poor vascular permeability; (ii) low and heterogeneous tumor uptake; (iii) cross-reactivity with normal tissues; (i.v.) metab. of monoclonal antibody conjugates; and (v) immunogenicity of murine forms in humans. As a result of extensive pharmaceutical and pharmacokinetic research conducted over the past 10 to 15 yr, several potential solns. to these delivery problems have been identified. Blood concns. of antibody conjugates may be reduced through regional administration, the use of antibody fragments, interventional strategies and various pre-targeting techniques.

Tumor uptake may be increased through administration of higher doses, or the use of agents to increase tumor vascular permeability. Tumor retention of antibody conjugates may be improved by inhibition of metab., by using more stable linkage chem. Alternatively, normal tissue retention may be decreased through the use of metabolisable chem. linkages inserted between the antibody and conjugated moiety. Very small antigen-binding fragments and peptides that exhibit improved tumor penetration and more rapid elimination from the blood and normal tissues have been prepd. by genetic engineering techniques. Chimeric (mouse/human) and human monoclonal antibodies have been developed to circumvent the problem of immunogenicity. Future research will continue to be focused on improvements in the design of monoclonal antibodies for tumor targeting, with the ultimate goal of finally uncovering the "magic bullet"

envisioned by Paul Ehrlich almost a century ago.

L10 ANSWER 17 OF 45 CAPLUS COPYRIGHT 1997 ACS
AN 1991:630351 CAPLUS
DN 115:230351
TI Method for selecting antibodies for delivering toxin to target cells
IN Uhr, Jonathan W.; Vitetta, Ellen S.
PA University of Texas System, USA
SO U.S., 8 pp.
CODEN: USXXAM
PI US 5045451 A 910903
AI US 88-262974 881026

DT Patent
LA English
AB A method for selecting immunotoxin (monoclonal) antibody capable of delivering a toxin to one type of target cells (e.g. tumor cells) comprises: (1) incubating target cells with an antibody in an aq. mixt. under conditions appropriate for immunocomplex formation; (2) introducing into the incubation mixt. a toxin (e.g. an A chain toxin; particularly ricin A chain) covalently linked to a 2nd antibody or its fragment (e.g. an Fab fragment) which has binding affinity for the 1st antibody; (3) detg. the ability of the antibody to deliver the toxin (by e.g. detn. of the inhibition of protein synthesis in the target cells); (4) repeating steps (1) - (3) for other antibodies and comparing the toxin-delivering abilities of those antibodies to select an antibody having the desired toxin-delivering ability. Thus, 14 mouse Igs specific to various animal cell (including human tumor cell) antigens were incubated with ricin A chain coupled with Fab fragments of goat anti-mouse Ig (GAMIg) to prep. immunotoxins. Eight cell lines were treated with the resp. immunotoxins. The toxin-delivering abilities were detd. by direct radioactivity assay of [3H]leucine incorporated in the cells and indirect immunofluorescence assay of the fluorescein isothiocyanate-coupled GAMIg fragments; several effective immunotoxins specific to human tumor cells were selected.

L10 ANSWER 25 OF 45 CAPLUS COPYRIGHT 1997 ACS
AN 1990:164781 CAPLUS
DN 112:164781
TI Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
AU Jain, Rakesh K.
CS Dep. Chem. Eng., Carnegie Mellon Univ., Pittsburgh, PA, 15213-3890, USA
SO Cancer Res. (1990), 50(3, Suppl.), 814s-819s
CODEN: CNREA8; ISSN: 0008-5472
DT Journal; General Review

LA English

~~AB~~ A review with 38 refs. The efficacy in cancer treatment of monoclonal antibodies or other macromols. bound to radionuclides, chemotherapeutic agents, toxins, enzyme, growth factor, or effector antibodies has been limited by their inability to reach their targets in vivo in adequate quantities. Three physiol. barriers responsible for the poor localization of macromols. in tumors are: (a) heterogeneous blood supply; (b) elevated interstitial pressure; and (c) large transport distances in the interstitium. The first barrier limits the delivery of blood-borne mols. to well-perfused regions of a tumor; the second barrier reduces extravasation of fluid and macromols. in the high interstitial pressure regions and also leads to an exptl. verifiable, radially outward convection in the tumor periphery which opposes the inward diffusion; and the third barrier increases the time required for slowly moving macromols. to reach distal regions of a tumor. Binding of antibody to an antigen further lowers the effective diffusion rate of the antibody by reducing the amt. of mobile antibody. The relative magnitude of each of these barriers varies from one location to another and from one day to the next in the same tumor and from one tumor to another. If the genetically engineered macromols., e.g., lymphokines, and other new modalities, e.g., killer lymphocytes, as well as low mol. wt. cytotoxic agents, are to fulfill their clin. promise, methods must be developed to overcome these physiol. barriers. Some of these methods are discussed, and situations wherein these barriers may not be a problem are pointed out.

L10 ANSWER 36 OF 45 CANCERLIT DUPLICATE 17
AN 88253318 CANCERLIT
TI THE INTRAPERITONEAL DELIVERY OF RADIOLABELED MONOCLONAL ANTIBODIES: STUDIES ON THE REGIONAL DELIVERY ADVANTAGE.
AU Wahl R L; Barrett J; Geatti O; Liebert M; Wilson B S; Fisher S; Wagner J G
CS University of Michigan Medical Center, Department of Internal Medicine, Ann Arbor 48109-0028.
NC RO1 CA41531-02
CA33802-04
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1988). Vol. 26, No. 3, pp. 187-201.
Journal code: CN3. ISSN: 0340-7004.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; Cancer Journals; L; Priority Journals
LA English
OS MEDLINE 88253318
EM 8809
AB The i.p. delivery of murine monoclonal antibody was compared with i.v. delivery in normal mice and rats, in normal nude mice and in

those with i.p. human ovarian carcinoma xenografts. In normal rats, all classes of antibodies and antibody fragments evaluated were cleared from the peritoneal cavity at comparable rates. The regional delivery (Rd1) advantage to the peritoneal cavity following i.p. delivery was thus most dependent on the rate of clearance of the antibody or fragment from the blood stream. Determining the exact i.p. delivery advantage was problematic due to the difficulty in reliably obtaining peritoneal fluid later than 9-10 h after i.p. injection in normal animals. During the first 9 h following i.p. injection, the Rd(0-9/0-9) was, for a murine IgG2ak Fab greater than F(ab')₂ greater than IgG (at 13.6 greater than 10 greater than 7.9). Two murine IgMs evaluated differed in Rd(0-9) at 27.1 and 9.2 respectively. When blood levels were extrapolated to infinity, these Rd (0-9/affinity) values were considerably lower with the Fab having the highest Rd at 4.67. The i.p. Rd advantage was almost solely due to the i.p. antibody levels seen in the first 24 h after injection, as after that time, blood levels become comparable to those seen following i.v. injection. Normal tissues obtained at sacrifice 5-7 days after i.p. or i.v. injection in rats showed comparable levels of radioantibody activity, whether the injection was i.p. or i.v. (except for higher diaphragmatic levels following i.p. delivery). In nude mice with i.p. human-derived ovarian tumors, intact IgG clearance from the peritoneal cavity to the blood was considerably slower than in normal animals, and early i.p. tumor uptake of specific antibody was significantly higher than that following i.v. antibody delivery. With higher early tumor uptake and lower systemic exposure, early tumor/nontumor ratios were significantly greater than those for i.v. delivery, though not beyond 48 h after i.p. injection. This study demonstrates the pharmacokinetic rationale for i.p. monoclonal antibody delivery, especially for agents cleared rapidly from the blood, such as antibody fragments. In addition, definite i.p. delivery benefit for antibody specific to i.p. tumors in the i.p. ovarian cancer system was shown soon after injection. These data regarding i.p. antibody delivery should be useful in rationally planning diagnostic and therapeutic studies involving the i.p. delivery of unmodified and immunoconjugated monoclonal antibodies.

L10 ANSWER 38 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.
AN 88030416 EMBASE
TI Improved radioimmunolocalization of human tumor xenografts following subcutaneous delivery of monoclonal antibodies.
AU Wahl R.L.; Laino L.; Fisher S.; Schteingart M.; Beierwaltes W.H.
CS University of Michigan Medical Center, Department of Internal Medicine, Division of Nuclear Medicine, Ann Arbor, MI 48109, United States
SO EUR. J. NUCL. MED., (1987) 13/10 (530-536).

ISSN: 0340-6997 CODEN: EJNMD

CY Germany, Federal Republic of

DT Journal

FS 016 Cancer

023 Nuclear Medicine

026 Immunology, Serology and Transplantation

LA English

AB The localization of a radiolabeled murine monoclonal antibody reactive with choriocarcinomas to human choriocarcinoma xenografts following intravenous and subcutaneous injection was evaluated by gamma scanning and tissue sampling. Tumor xenografts were established in the popliteal node region of athymic nude mice after repeated inoculations of the hind foot pads with BEWO choriocarcinoma cells. In dual label specific antibody studies, tumor/non tumor uptake ratios following subcutaneous (resulting in considerable intralymphatic uptake) injection of ^{131}I -5F9.3 were significantly higher than those achieved post simultaneous intravenous injection of ^{125}I -5F9.3. Double label experiments with ^{131}I -5F9.3 and a nonspecific antibody, ^{125}I -UPC-10, following subcutaneous injection, demonstrated that the high localization to popliteal region tumors was largely due to antibody specificity. Gamma scans following subcutaneous antibody administration of specific antibody to tumor bearing animals showed tumors soon after subcutaneous injection, at times earlier than those typically seen following intravenous delivery. Similar subcutaneous injections showed little normal nodal uptake in BALB/c control animals on gamma scans. No correlation was seen between tumor localization by specific antibody between the intravenous and intralymphatic routes, implying a difference in the mechanisms of tumor uptake of antibody by these two routes. The subcutaneous approach to antibody delivery offers advantages over intravenous delivery in tumors of human origin, including higher tumor/non tumor ratios and earlier imaging times. This was true even though these tumors were many times larger than normal lymph nodes. This subcutaneous delivery advantage should be exploitable in imaging nodal metastases of human tumors.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.56

61.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.45

-1.45

STN INTERNATIONAL LOGOFF AT 15:19:06 ON 02 JAN 97

XCS Service v1.00
con .cas
9351006 COM

Welcome to STN International! Enter x:x

LOGINID:ssspta1800mxz

PASSWORD:

avueb925

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'HOME' AT 15:14:20 ON 02 JAN 97
FILE 'HOME' ENTERED AT 15:14:20 ON 02 JAN 97

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	50.32

=> d l2 bib ab 5 17 25 36 38

'L2' HAS NO ANSWERS

L2 QUE ANTIBODY DELIVERY AND (CANCER OR TUMOR)

=> d l10 bib ab 5 17 25 36 38

NO ANSWERS DISPLAYED.

THE ANSWER SET WAS CREATED IN FILE 'CANCERLIT, BIOSIS, EMBASE, MEDLINE, CAPLUS, SCISEARCH'.

USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.

You have entered a file that is not in the current file environment.

Enter "DISPLAY HISTORY" to see a list of the files in the current environment.

=> file cancerlit biosis embase medline caplus scisearch

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.75	50.92

FILE 'CANCERLIT' ENTERED AT 15:17:26 ON 02 JAN 97

FILE 'BIOSIS' ENTERED AT 15:17:26 ON 02 JAN 97
COPYRIGHT (C) 1997 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:17:26 ON 02 JAN 97
COPYRIGHT (C) 1997 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 15:17:26 ON 02 JAN 97

FILE 'CAPLUS' ENTERED AT 15:17:26 ON 02 JAN 97
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

=> file uspatfull

COST IN U.S. DOLLARS

SINCE FILE
ENTRYTOTAL
SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'USPATFULL' ENTERED AT 14:40:27 ON 02 JAN 97

CA INDEXING COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Dec 1996 (19961224/PD)

FILE LAST UPDATED: 27 Dec 1996 (961227/ED)

HIGHEST PATENT NUMBER: US5588152

CA INDEXING IS CURRENT THROUGH 27 Dec 1996 (961227/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Dec 1996 (19961224/PD)

REVISED CLASS FIELDS (/NCL) CURRENT THROUGH: DEC 1996

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: OCT 1996

>>> Page images are available for patents from 1/1/93. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

=> s antibody delivery and (cancer or tumor)

17690 ANTIBODY

111607 DELIVERY

2 ANTIBODY DELIVERY

(ANTIBODY (W) DELIVERY)

16929 CANCER

13493 TUMOR

L1 2 ANTIBODY DELIVERY AND (CANCER OR TUMOR)

=> d 1-2

L1 ANSWER 1 OF 2 USPATFULL

AN 92:1030 USPATFULL

TI Selective removal of radiolabeled antibodies

IN Abrams, Paul G., Seattle, WA, United States

PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 5078673 920107
 AI US 89-328827 890327 (7)
 RLI Continuation-in-part of Ser. No. US 88-270144, filed on 14 Nov
 1988, now abandoned
 DT Utility
 LN.CNT 638
 INCL INCLM: 600/003.000
 INCLS: 604/004.000; 128/659.000
 NCL NCLM: 600/003.000
 NCLS: 128/654.000; 604/004.000
 IC [5]
 ICM: A61N005-00
 EXP 128/653; 128/654; 128/659; 600/1-6; 604/4-6; 604/19; 604/20;
 604/27; 604/28; 424/1.1; 424/985.8; 436/547; 436/548

L1 ANSWER 2 OF 2 USPATFULL
 AN 91:79780 USPATFULL
 TI Monoclonal antibodies binding platinum complexes
 IN Rosenblum, Michael G., Houston, TX, United States
 Murray, James L., Houston, TX, United States
 Kelleher, Peter J., The Woodlands, TX, United States
 Newman, Robert A., Houston, TX, United States
 Khokhar, Abdul R., Houston, TX, United States
 PA Board of Regents, The University of Texas System, Austin, TX,
 United States (U.S. corporation)
 PI US 5053226 911001
 AI US 87-73500 870715 (7)
 DT Utility
 LN.CNT 1226
 INCL INCLM: 424/085.800
 INCLS: 424/086.000; 424/087.000; 435/240.270; 435/240.260
 NCL NCLM: 530/388.900
 NCLS: 424/141.100; 435/240.260; 435/240.270
 IC [5]
 ICM: A61K039-40
 ICS: A61K039-42; A61K039-44; C12N005-00
 EXP 435/240.26; 435/240.27; 424/85.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file home

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

4.35

4.50

FILE 'HOME' ENTERED AT 14:41:59 ON 02 JAN 97

=> index bioscience

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	4.65

INDEX 'AIDSLINE, ANABSTR, AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHABS, BIOTECHDS, CABA, CANCERLIT, CAPLUS, CEABA, CEN, CIN, CJACS, CJELSEVIER, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGLAUNCH, DRUGNL, DRUGU, EMBAL, EMBASE, FSTA, GENBANK, ...' ENTERED AT 14:42:07 ON 02 JAN 97

45 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s antibody delivery and (cancer or tumor)

- 2 FILE BIOBUSINESS
- 17 FILE BIOSIS
- 19 FILE CANCERLIT
- 14 FILE CAPLUS
- 1 FILE CEN
- 2 FILE CIN
- 2 FILE CJACS

15 FILES SEARCHED...

- 1 FILE CONFSCI
- 2 FILE DDFU
- 1 FILE DRUGNL
- 4 FILE DRUGU
- 16 FILE EMBASE
- 3 FILE LIFESCI
- 16 FILE MEDLINE

36 FILES SEARCHED...

- 1 FILE NTIS
- 6 FILE PHIN
- 9 FILE PROMT
- 12 FILE SCISEARCH
- 8 FILE TOXLINE
- 5 FILE TOXLIT
- 2 FILE USPATFULL

21 FILES HAVE ONE OR MORE ANSWERS, 45 FILES SEARCHED IN STNINDEX

L2 QUE ANTIBODY DELIVERY AND (CANCER OR TUMOR)

=> d rank

F1 19 CANCERLIT

F2	17	BIOSIS
F3	16	EMBASE
F4	16	MEDLINE
F5	14	CAPLUS
F6	12	SCISEARCH
F7	9	PROMT
F8	8	TOXLINE
F9	6	PHIN
F10	5	TOXLIT
F11	4	DRUGU
F12	3	LIFESCI
F13	2	BIOBUSINESS
F14	2	CIN
F15	2	CJACS
F16	2	DDFU
F17	2	USPATFULL
F18	1	CEN
F19	1	CONFSCI
F20	1	DRUGNL
F21	1	NTIS

=> file cancerlit biosis embase medline caplus scisearch

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

1.80

6.45

FILE 'CANCERLIT' ENTERED AT 14:44:19 ON 02 JAN 97

FILE 'BIOSIS' ENTERED AT 14:44:19 ON 02 JAN 97

COPYRIGHT (C) 1997 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 14:44:19 ON 02 JAN 97

COPYRIGHT (C) 1997 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 14:44:19 ON 02 JAN 97

FILE 'CAPLUS' ENTERED AT 14:44:19 ON 02 JAN 97

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 14:44:19 ON 02 JAN 97

COPYRIGHT (C) 1997 Institute for Scientific Information (ISI) (R)

=> s 12

L3	19	FILE CANCERLIT
L4	17	FILE BIOSIS
L5	16	FILE EMBASE
L6	16	FILE MEDLINE

L7 14 FILE CAPLUS
L8 12 FILE SCISEARCH

TOTAL FOR ALL FILES

L9 94 L2

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 45 DUP REM L9 (49 DUPLICATES REMOVED)

=> d bib 1-45

L10 ANSWER 1 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.DUPLICATE 1
AN 96268763 EMBASE
TI Pharmacokinetics of monoclonal antibodies. Implications for their
use in cancer therapy.
AU Pedley R.B.
CS CRC Targeting and Imaging Group, Department of Clinical Oncology,
Royal Free Hosp. School of Medicine, Rowland Hill Street, London NW3
2PF, United Kingdom
SO Clinical Immunotherapeutics, (1996) 6/1 (54-67).
ISSN: 1172-7039 CODEN: CIMMEA
CY New Zealand
DT Journal
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L10 ANSWER 2 OF 45 CAPLUS COPYRIGHT 1997 ACS
AN 1995:782967 CAPLUS
DN 123:217643
TI Effect of increasing vascular hydraulic conductivity on delivery of
macromolecular drugs to tumor cells
AU El-Kareh, Ardith W.; Secomb, Timothy W.
CS Department of Physiology, University of Arizona, Tucson, AZ, 85724,
USA
SO Int. J. Radiat. Oncol., Biol., Phys. (1995), Volume Date 1995,
32(5), 1419-23
CODEN: IOBPD3; ISSN: 0360-3016
DT Journal
LA English

L10 ANSWER 3 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS
AN 95:186216 BIOSIS
DN 98200516
TI Combination of doxorubicin-immunoconjugates and molecular

intervention in bcl-2 oncogene expression to overcome drug resistance
in small cell lung cancer.

AU Froesch B; Stahel R A; Ludke G; Zangemeister-Wittke U
CS Div. Oncol., Dep. Intern. Med., Univ. Hosp., Zurich, Switzerland
SO Eighty-sixth Annual Meeting of the American Association for Cancer
Research, Toronto, Ontario, Canada, March 18-22, 1995. Proceedings of
the American Association for Cancer Research Annual Meeting 36 (0).
1995. 341. ISSN: 0197-016X
DT Conference
LA English

L10 ANSWER 4 OF 45 CANCERLIT DUPLICATE 2

AN 96418220 CANCERLIT
TI Prolongation of murine cardiac allograft survival by microspheres
containing TNF alpha and IL1-beta neutralizing antibodies.
AU Gerber D A; Oettinger C W; D'Souza M; Milton G V; Larsen C P;
Pearson T C
CS Department of Surgery, Emory University School of Medicine, Atlanta,
GA 30322, USA.
NC 1R29 AI33588-01A1 (NIAID)
AR42687 (NIAMS)
SO JOURNAL OF DRUG TARGETING, (1995). Vol. 3, No. 4, pp. 311-5.
Journal code: B3S. ISSN: 1061-186X.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority Journals
LA English
OS MEDLINE 96418220
EM 9612

L10 ANSWER 5 OF 45 CAPLUS COPYRIGHT 1997 ACS

AN 1995:403077 CAPLUS
DN 122:169735
TI Problems of delivery of monoclonal antibodies: Pharmaceutical and
pharmacokinetic solutions
AU Reilly, Raymond M.; Sandhu, Jasbir; Alvarez-Diez, Teresa M.;
Gallinger, Steven; Kirsh, Joel; Stern, Hartley
CS Faculty Pharmacy, University Toronto, Toronto, ON, Can.
SO Clin. Pharmacokinet. (1995), 28(2), 126-42
CODEN: CPKNDH; ISSN: 0312-5963
DT Journal; General Review
LA English

L10 ANSWER 6 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 3

AN 95:419780 BIOSIS
DN 98434080
TI Antibody delivery through the blood-brain
barrier.
AU Bickel U

CS Inst. Physiol., Philipps-Univ. Marburg, Deutschhausstr. 2, 35033
Marburg, Germany

SO Advanced Drug Delivery Reviews 15 (1-3). 1995. 53-72. ISSN:
0169-409X

LA English

L10 ANSWER 7 OF 45 CANCERLIT

AN 96617362 CANCERLIT

TI Chimeras, castor beans, and cancer: antibody and
ligand-toxin conjugates as therapeutic agents.

AU Griffin T W; Recht L; Maher E; Delichatsios H; Raso V

CS University of Massachusetts Medical Center, Worcester, MA.

SO Non-serial, (1994). Molecular and Immunologic Approaches. Huber BE,
Carr BI., eds. (Cancer Therapy in the Twenty-First Century, Vol I)
Mount Kisco, NY, Futura Publishing, p.227-73, 1994.
ISBN: 0-87993-564-2.

DT Book; (MONOGRAPH)

FS ICDB

LA English

EM 9605

L10 ANSWER 8 OF 45 CANCERLIT

DUPLICATE 4

AN 94320070 CANCERLIT

TI Monoclonal antibody delivery to intraperitoneal
tumors in rats: effects of route of administration and
intraperitoneal solution osmolality.

AU Flessner M F; Dedrick R L

CS Laboratory of Kidney and Electrolyte Metabolism, National Heart,
Lung, and Blood Institute, NIH, Bethesda, Maryland 20892.

SO CANCER RESEARCH, (1994). Vol. 54, No. 16, pp. 4376-84.
Journal code: CNF. ISSN: 0008-5472.

DT Journal; Article; (JOURNAL ARTICLE)

FS MEDL; Cancer Journals; L; Priority Journals

LA English

OS MEDLINE 94320070

EM 9410

L10 ANSWER 9 OF 45 CANCERLIT

DUPLICATE 5

AN 94228538 CANCERLIT

TI Streptavidin distribution in metastatic tumors pretargeted with a
biotinylated monoclonal antibody: theoretical and experimental
pharmacokinetics.

AU Sung C; van Osdol W W; Saga T; Neumann R D; Dedrick R L; Weinstein J
N

CS Biomedical Engineering and Instrumentation Program, National Center
for Research Resources, NIH, Bethesda, Maryland 20892.

SO CANCER RESEARCH, (1994). Vol. 54, No. 8, pp. 2166-75.
Journal code: CNF. ISSN: 0008-5472.

DT Journal; Article; (JOURNAL ARTICLE)

FS MEDL; Cancer Journals; L; Priority Journals

LA English

OS MEDLINE 94228538

EM 9407

L10 ANSWER 10 OF 45 CANCERLIT

DUPLICATE 6

AN 95017264 CANCERLIT

TI Effects of radiolabelled murine antibody infusion on TNF-alpha, IL-1 beta, and soluble IL-2 receptor in cancer patients.

AU Gridley D S; Hammond S N; Slater J M

CS Department of Microbiology, Loma Linda University/Independent Order of Foresters Cancer Research Laboratory, Loma Linda University School of Medicine, California 92350.

SO JOURNAL OF CLINICAL LABORATORY ANALYSIS, (1994). Vol. 8, No. 4, pp. 223-7.

Journal code: JLA. ISSN: 0887-8013.

DT Journal; Article; (JOURNAL ARTICLE)

FS MEDL; L; Priority Journals

LA English

OS MEDLINE 95017264

EM 9412

L10 ANSWER 11 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS

AN 94:240411 BIOSIS

DN 97253411

TI Monoclonal antibodies against proliferation associated antigens tumor physiology and pharmacokinetics as limiting factors of antibody delivery.

AU Hans F J; Warnke P C; Rensing H; Bigner D D; Ostertag C B

CS Dep. Neurosurg., Univ. Freiburg, Freiburg, GER

SO 21st National Cancer Congress of the German Cancer Society, Hamburg, Germany, March 7-11, 1994. Journal of Cancer Research and Clinical Oncology 120 (SUPPL.). 1994. R12. ISSN: 0171-5216

DT Conference

LA English

L10 ANSWER 12 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.DUPLICATE 7

AN 93071483 EMBASE

TI Histamine but neither angiotensin nor vasopressin increases antibody uptake into xenograft colorectal liver metastases.

AU Hennigan T.W.; Begent R.H.J.; Allen-Merish T.G.

CS Department of Surgery, Charing Cross/Westminster Med. Sch., Fulham Palace Road, London W6 8RF, United Kingdom

SO BR. J. SURG., (1993) 80/1 (72-74).

ISSN: 0007-1323 CODEN: BJSUAM

CY United Kingdom

DT	Journal	
FS	009	Surgery
	037	Drug Literature Index
LA	English	
SL	English	
<hr/>		
L10	ANSWER 13 OF 45	CANCERLIT DUPLICATE 8
AN	94031446	CANCERLIT
TI	Treatment of leukemia with radiolabeled monoclonal antibodies.	
AU	Sgouros G; Scheinberg D A	
CS	Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.	
<hr/>		
SO	CANCER TREATMENT AND RESEARCH, (1993). Vol. 68, pp. 23-64.	
	Journal code: AVA.	
DT	Journal; Article; (JOURNAL ARTICLE)	
	General Review; (REVIEW)	
	(REVIEW, TUTORIAL)	
FS	MEDL; L; Priority Journals	
LA	English	
OS	MEDLINE 94031446	
EM	9401	
<hr/>		
L10	ANSWER 14 OF 45	MEDLINE DUPLICATE 9
AN	93103676	MEDLINE
TI	Controlled antibody delivery systems.	
AU	Sherwood J K; Dause R B; Saltzman W M	
CS	Department of Chemical Engineering, Johns Hopkins University, Baltimore, MD 21218..	
NC	GM-43873 (NIGMS)	
	CA-52857 (NCI)	
SO	BIO/TECHNOLOGY, (1992 Nov) 10 (11) 1446-9.	
	Journal code: AL1. ISSN: 0733-222X.	
CY	United States	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	B	
EM	9303	
<hr/>		
L10	ANSWER 15 OF 45	CAPLUS COPYRIGHT 1997 ACS
AN	1992:262369	CAPLUS
DN	116:262369	
TI	Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems	
AU	Jiang, Frank N.; Allison, Beth; Liu, Daniel; Levy, Julia G.	
CS	Dep. Microbiol., Univ. British Columbia, Vancouver, BC, Can.	
SO	J. Controlled Release (1992), 19(1-3), 41-58	
	CODEN: JCREEC; ISSN: 0168-3659	
DT	Journal	

LA English

L10 ANSWER 16 OF 45 SCISEARCH COPYRIGHT 1997 ISI (R)
AN 92:672169 SCISEARCH
GA The Genuine Article (R) Number: JX858
TI IMAGING AND MOVEMENT OF IRON-OXIDE-BOUND ANTIBODY MICROPARTICLES IN
BRAIN AND CEREBROSPINAL-FLUID
AU ENGELHARD H H (Reprint); PETRUSKA D A
CS UNIV LOUISVILLE, DEPT SURG, DIV NEUROSURG, LOUISVILLE, KY, 40292
CYA USA
SO CANCER BIOCHEMISTRY BIOPHYSICS, (1992) Vol. 13, No. 1, pp. 1-12.
ISSN: 0305-7232.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 49

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 17 OF 45 CAPLUS COPYRIGHT 1997 ACS
AN 1991:630351 CAPLUS
DN 115:230351
TI Method for selecting antibodies for delivering toxin to target cells
IN Uhr, Jonathan W.; Vitetta, Ellen S.
PA University of Texas System, USA
SO U.S., 8 pp.
CODEN: USXXAM
PI US 5045451 A 910903
AI US 88-262974 881026
DT Patent
LA English

L10 ANSWER 18 OF 45 CANCERLIT
AN 91674369 CANCERLIT
TI THE IMPACT OF DEXAMETHASONE ON THE LOCALIZATION OF MONOCLONAL
ANTIBODY L6 TO INTRACEREBRAL AND SC HUMAN SMALL-CELL LUNG XENOGRAFTS
(MEETING ABSTRACT).
AU Neuwelt E; Barnett P; Ramsey F; Hellstrom I; Karl E; McCormick C
CS Dept. of Neurology, Oregon Health Sciences Univ., Portland, OR
97201.
SO Proc Annu Meet Am Assoc Cancer Res, (1991). Vol. 32, pp. A1560.
ISSN: 0197-016X.
DT (MEETING ABSTRACT)
FS ICDB
LA English
EM 9107

L10 ANSWER 19 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS
AN 91:399480 BIOSIS

DN BR41:61325

TI IMPROVED STABILITY THROUGH MODIFICATION OF THE LINKER IN
HAPTEN-CHELATE CONSTRUCTS FOR BIFUNCTIONAL ANTIBODY
DELIVERY.

AU SULLIVAN B W; BALASUBRAMANIAN P N; DRIUSSI D; ANDERSON L D

CS HYBRITECH INC., P.O. BOX 269006, SAN DIEGO, CALIF.

SO 38TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE, CINCINNATI,
OHIO, USA, JUNE 11-14, 1991. J NUCL MED 32 (5 SUPPL.). 1991. 1023.
CODEN: JNMEAQ ISSN: 0161-5505

DT Conference

LA English

L10 ANSWER 20 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS

AN 91:399029 BIOSIS

DN BR41:60874

TI COMPARISON OF DOTA AND DTPA ANALOGS FOR BIFUNCTIONAL ANTIBODY
DELIVERY OF INDIUM-111 AND YTTRIUM-90.

AU ANDERSON L D; BALASUBRAMANIAN P N; MOI M K; SULLIVAN B W; MACKENSEN D

CS HYBRITECH INC., P.O. BOX 269006, SAN DIEGO, CALIF.

SO 38TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE, CINCINNATI,
OHIO, USA, JUNE 11-14, 1991. J NUCL MED 32 (5 SUPPL.). 1991.
915-916. CODEN: JNMEAQ ISSN: 0161-5505

DT Conference

LA English

L10 ANSWER 21 OF 45 SCISEARCH COPYRIGHT 1997 ISI (R)

AN 92:306723 SCISEARCH

GA The Genuine Article (R) Number: HT510

TI REVIEW OF EXPERIMENTAL METHODS TO DETERMINE RADIATION ABSORBED DOSE
IN RADIOIMMUNOTHERAPY

AU HUMM J L (Reprint); CHIN L M

CS HARVARD UNIV, SCH MED, JOINT CTR RADIAT THERAPY, 50 BINNEY ST,
BOSTON, MA, 02115 (Reprint)

CYA USA

SO ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, (WIN 1991) Vol.
4, No. 4, pp. 613-621.
ISSN: 0892-7049.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 33

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 22 OF 45 CANCERLIT

DUPLICATE 10

AN 91131193 CANCERLIT

TI QUANTITATIVE MEASUREMENT OF MONOCLONAL ANTIBODY DISTRIBUTION AND
BLOOD FLOW USING POSITRON EMISSION TOMOGRAPHY AND 124IODINE IN
PATIENTS WITH BREAST CANCER.

AU Wilson C B; Snook D E; Dhokia B; Taylor C V; Watson I A; Lammertsma
A A; Lambrecht R; Waxman J; Jones T; Epenetos A A
CS ICRF Oncology Group, Hammersmith Hospital London, UK.
SO INTERNATIONAL JOURNAL OF CANCER, (1991). Vol. 47, No. 3, pp. 344-7.
Journal code: GQU. ISSN: 0020-7136.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; Cancer Journals; L; Priority Journals
LA English
OS MEDLINE 91131193
EM 9104

L10 ANSWER 23 OF 45 CANCERLIT DUPLICATE 11

AN 92118243 CANCERLIT
TI CUSTOM-TAILORED DRUG IMMUNOCONJUGATES IN CANCER THERAPY.
AU Oldham R K
CS Biological Therapy Institute, Franklin, Tennessee 37065-1700.
SO MOLECULAR BIOTHERAPY, (1991). Vol. 3, No. 3, pp. 148-62.
Journal code: AH5. ISSN: 0952-8172.
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority Journals
LA English
OS MEDLINE 92118243
EM 9203

L10 ANSWER 24 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.
AN 90313767 EMBASE
TI Quantification of transport and binding parameters using
Fluorescence Recovery After Photobleaching. Potential for in vivo
applications.
AU Kaufman E.N.; Jain R.K.
CS Department of Chemical Engineering, Carnegie Mellon University,
Pittsburgh, PA 15213-3890, United States
SO BIOPHYS. J., (1990) 58/4 (873-885).
ISSN: 0006-3495 CODEN: BIOJAU
CY United States
DT Journal
FS 016 Cancer
027 Biophysics, Bioengineering and Medical Instrumentation
LA English

L10 ANSWER 25 OF 45 CAPLUS COPYRIGHT 1997 ACS
AN 1990:164781 CAPLUS
DN 112:164781
TI Physiological barriers to delivery of monoclonal antibodies and
other macromolecules in tumors
AU Jain, Rakesh K.
CS Dep. Chem. Eng., Carnegie Mellon Univ., Pittsburgh, PA, 15213-3890,

USA

SO Cancer Res. (1990), 50(3, Suppl.), 814s-819s
CODEN: CNREA8; ISSN: 0008-5472

DT Journal; General Review

LA English

L10 ANSWER 26 OF 45 CAPLUS COPYRIGHT 1997 ACS

AN 1990:484671 CAPLUS

DN 113:84671

TI Antibody-directed enzyme/prodrug therapy (ADEPT)

AU Bagshawe, K. D.

CS Dep. Med. Oncol., Charing Cross Hosp., London, W6 8RF, UK

SO Biochem. Soc. Trans. (1990), 18(5), 750-2

CODEN: BCSTB5; ISSN: 0300-5127

DT Journal; General Review

LA English

L10 ANSWER 27 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.

AN 90358929 EMBASE

TI Chemotherapy and monoclonal antibody delivery to
malignant brain tumors: The role of blood-brain barrier
modification.

AU Neuwelt E.A.; Barnett P.A.; Dahlborg S.A.

CS Division of Neurosurgery, Oregon Health Sciences University,
Portland, OR 97201-3098, United States

SO FERNSTROM FOUND. SER., (1990) 14/- (187-196).

ISSN: 0167-7004 CODEN: FFOSDF

CY Netherlands

DT Journal

FS 008 Neurology and Neurosurgery

016 Cancer

LA English

L10 ANSWER 28 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS

AN 91:6954 BIOSIS

DN BA91:6954

TI DIRECT STEREOTACTIC INTRACEREBRAL INJECTION OF MONOCLONAL ANTIBODIES
AND THEIR FRAGMENTS A POTENTIAL APPROACH TO BRAIN TUMOR
IMMUNOTHERAPY.

AU LIEBERT M; WAHL R L; LAWLESS G; MCKEEVER P E; TAREN J A; BEIERWALTES
W H; BRASSWELL R

CS DIV. OF NUCLEAR MED., BOX 0028 B1G412, UNIV. OF MICHIGAN, ANN ARBOR,
MICH. 48109.

SO AM J PHYSIOL IMAGING 5 (2). 1990. 55-59. CODEN: AJPIEW ISSN:
0885-8276

LA English

L10 ANSWER 29 OF 45 CANCERLIT

DUPLICATE 12

AN 90256001 CANCERLIT
TI TUMOR PHYSIOLOGY AND ANTIBODY DELIVERY
(37 Refs).
AU Jain R K
CS Department of Chemical Engineering, Carnegie Mellon University,
Pittsburgh, Pa.
SO FRONTIERS OF RADIATION THERAPY AND ONCOLOGY, (1990). Vol. 24, pp.
32-46.
Journal code: FPK. ISSN: 0071-9679.
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
FS MEDL; L; Priority Journals
LA English
OS MEDLINE 90256001
EM 9007

L10 ANSWER 30 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS
AN 90:253220 BIOSIS
DN BR38:119808
TI TUMOR PHYSIOLOGY AND ANTIBODY DELIVERY.
AU JAIN R K
CS DEP. CHEM. ENGINEERING, CARNEGIE MELLON UNIV., PITTSBURGH, PA.
15213-3890, USA.
SO VAETH, J. M. AND J. L. MEYER (ED.). FRONTIERS OF RADIATION THERAPY
AND ONCOLOGY, VOL. 24. THE PRESENT AND FUTURE ROLE OF MONOCLONAL
ANTIBODIES IN THE MANAGEMENT OF CANCER; 24TH ANNUAL SAN FRANCISCO
CANCER SYMPOSIUM, SAN FRANCISCO, CALIFORNIA, USA, FEBRUARY 10-11,
1989. IX+265P. S. KARGER AG: BASEL, SWITZERLAND; NEW YORK, NEW YORK,
USA. ILLUS. 0 (0). 1990. 32-46. CODEN: FRTOA7 ISBN: 3-8055-5029-4
ISSN: 0071-9676
DT Conference
LA English

L10 ANSWER 31 OF 45 CANCERLIT DUPLICATE 13
AN 90206382 CANCERLIT
TI MONOCLONAL ANTIBODIES IN NEURO-ONCOLOGY.
AU Stavrou D
CS Department of Neuropathology, University of Hamburg, University
Hospital Eppendorf, West Germany.
SO NEUROSURGICAL REVIEW, (1990). Vol. 13, No. 1, pp. 7-18.
Journal code: NOV. ISSN: 0344-5607.
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
FS MEDL; L; Priority Journals
LA English
OS MEDLINE 90206382

EM 9006

L10 ANSWER 32 OF 45 CANCERLIT DUPLICATE 14
AN 89360685 CANCERLIT
TI INDIVIDUALLY SPECIFIED DRUG IMMUNOCONJUGATES IN CANCER
TREATMENT.
AU Oldham R K; Lewis M; Orr D W; Liao S K; Ogden J R; Hubbard W H;
Birch R
CS Williamson Medical Center, Franklin, TN.
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, (1989). Vol. 4, No. 2,
pp. 65-77.

Journal code: IJM. ISSN: 0393-6155.

DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority Journals
LA English
OS MEDLINE 89360685
EM 8911

L10 ANSWER 33 OF 45 CANCERLIT DUPLICATE 15
AN 88310824 CANCERLIT
TI DELIVERY OF MELANOMA-ASSOCIATED IMMUNOGLOBULIN MONOCLONAL ANTIBODY
AND FAB FRAGMENTS TO NORMAL BRAIN UTILIZING OSMOTIC BLOOD-BRAIN
BARRIER DISRUPTION.

AU Neuwelt E A; Barnett P A; Hellstrom I; Hellstrom K E; Beaumier P;
McCormick C I; Weigel R M
CS Oregon Health Sciences University, Division of Neurosurgery,
Portland 97201.

NC- CA31770
CA38011
SO CANCER RESEARCH, (1988). Vol. 48, No. 17, pp. 4725-9.
Journal code: CNF. ISSN: 0008-5472.

DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; Cancer Journals; L; Priority Journals
LA English
OS MEDLINE 88310824
EM 8811

L10 ANSWER 34 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.
AN 88120037 EMBASE
TI Antibody delivery and effector cell activation
in a phase II trial of recombinant .gamma.-interferon and the murine
monoclonal antibody CO17-1A in advanced colorectal carcinoma.
AU Weiner L.M.; Moldofsky P.J.; Gatenby R.A.; O'Dwyer J.; O'Brien J.;
Litwin S.; Comis R.L.
CS Department of Medical Oncology, Fox Chase Cancer Center,
Philadelphia, PA 19111, United States
SO CANCER RES., (1988) 48/9 (2568-2573).
ISSN: 0008-5472 CODEN: CNREA8

CY United States

DT Journal

FS 016 Cancer
026 Immunology, Serology and Transplantation
048 Gastroenterology
030 Pharmacology

LA English

L10 ANSWER 35 OF 45 CANCERLIT DUPLICATE 16

AN 88225173 CANCERLIT

TI IMPROVED RADIOIMMUNOLOCALIZATION OF HUMAN TUMOR XENOGRAPTS
FOLLOWING SUBCUTANEOUS DELIVERY OF MONOCLONAL ANTIBODIES.

AU Wahl R L; Laino L; Fisher S; Schteingart M; Beierwaltes W H
CS University of Michigan Medical Center, Department of Internal
Medicine, Ann Arbor 48109.

NC CA40497
CA33802

SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE, (1988). Vol. 13, No. 10, pp.
530-6.

Journal code: ENC. ISSN: 0340-6997.

DT Journal; Article; (JOURNAL ARTICLE)

FS MEDL; L; Priority Journals

LA English

OS MEDLINE 88225173

EM 8808

L10 ANSWER 36 OF 45 CANCERLIT DUPLICATE 17

AN 88253318 CANCERLIT

TI THE INTRAPERITONEAL DELIVERY OF RADIOLABELED MONOCLONAL ANTIBODIES:
STUDIES ON THE REGIONAL DELIVERY ADVANTAGE.

AU Wahl R L; Barrett J; Geatti O; Liebert M; Wilson B S; Fisher S;
Wagner J G

CS University of Michigan Medical Center, Department of Internal
Medicine, Ann Arbor 48109-0028.

NC RO1 CA41531-02
CA33802-04

SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1988). Vol. 26, No. 3, pp.
187-201.

Journal code: CN3. ISSN: 0340-7004.

DT Journal; Article; (JOURNAL ARTICLE)

FS MEDL; Cancer Journals; L; Priority Journals

LA English

OS MEDLINE 88253318

EM 8809

L10 ANSWER 37 OF 45 CANCERLIT DUPLICATE 18

AN 87130791 CANCERLIT

TI COMPARISON OF MONOCLONAL ANTIBODY DELIVERY TO

INTRACRANIAL GLIOMA XENOGRAPTS BY INTRAVENOUS AND INTRACAROTID
ADMINISTRATION.

AU Lee Y S; Bullard D E; Wikstrand C J; Zalutsky M R; Muhlbaier L H;
Bigner D D
CS Preuss Laboratory for Brain Tumor Research, Duke University, Durham,
North Carolina 27710.
NC CA 32672-05
NS 20023-01
RO1-CA 11898-15
+
SO CANCER RESEARCH, (1987). Vol. 47, No. 7, pp. 1941-6.
~~Journal code: CNF. ISSN: 0008-5472.~~
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; Cancer Journals; L; Priority Journals
LA English
OS MEDLINE 87130791
EM 8705

L10 ANSWER 38 OF 45 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.
AN 88030416 EMBASE
TI Improved radioimmunolocalization of human tumor xenografts
following subcutaneous delivery of monoclonal antibodies.
AU Wahl R.L.; Laino L.; Fisher S.; Schteingart M.; Beierwaltes W.H.
CS University of Michigan Medical Center, Department of Internal
Medicine, Division of Nuclear Medicine, Ann Arbor, MI 48109, United
States
SO EUR. J. NUCL. MED., (1987) 13/10 (530-536).
ISSN: 0340-6997 CODEN: EJNMD
CY Germany, Federal Republic of
DT Journal
FS 016 Cancer
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
LA English

L10 ANSWER 39 OF 45 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 19
AN 87:371043 BIOSIS
DN BR33:61518
TI ENHANCED RADIOIMMUNOTHERAPY OF INTRAPERITONEAL HUMAN COLON
CANCER XENOGRAPTS BY INTRAPERITONEAL MONOCLONAL
ANTIBODY DELIVERY.
AU WAHL R L; LIEBERT M; FISHER S; BOLAND R
CS UNIV. MICH. MED. CENT., ANN ARBOR, MI 48109.
SO SEVENTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER
RESEARCH, ATLANTA, GEORGIA, USA, MAY 20-23, 1987. PROC AM ASSOC
CANCER RES ANNU MEET 28 (0). 1987. 438. CODEN: PAMREA
DT Conference
LA English

L10 ANSWER 40 OF 45 CANCERLIT
AN 87632900 CANCERLIT
TI NEUTRON CAPTURE THERAPY.
AU Anonymous
CS No affiliation given.
SO Non-serial, (1986). Neutron Capture Therapy. Hatanaka H, ed.
Niigata, Japan, Nishimura Co., Ltd., 449 p., 1986.
DT Book; (MONOGRAPH)
FS ICDB
LA English
EM 8705

L10 ANSWER 41 OF 45 CANCERLIT DUPLICATE 20
AN 86244814 CANCERLIT
TI AUTORADIOGRAPHIC ANALYSIS OF MONOCLONAL ANTIBODY DISTRIBUTION IN
HUMAN COLON AND BREAST TUMOR XENOGRAFTS.
AU Jones P L; Gallagher B M; Sands H
CS E.I. du Pont de Nemours and Co. (Inc.), Biomedical Products
Department, North Billerica, Massachusetts 01862.
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1986). Vol. 22, No. 2, pp.
139-43.
Journal code: CN3. ISSN: 0340-7004.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; Cancer Journals; L; Priority Journals
LA English
OS MEDLINE 86244814
EM 8609

L10 ANSWER 42 OF 45 CANCERLIT
AN 86622674 CANCERLIT
TI USE OF MONOCLONAL ANTIBODIES TO DETECT METASTASES OF SOLID TUMORS IN
LYMPH NODES.
AU Weinstein J N; Keenan A M; Holton OD I I I; Covell D G; Sieber S M;
Black C D V; Barbet J; Talley M J; Parker R J
CS Lab. of Mathematical Biology, NCI, NIH, Bethesda, MD 20205.
SO Dev Oncol, (1985). Vol. 35, pp. 218-32.
DT (MEETING PAPER)
FS ICDB
LA English
EM 8610

L10 ANSWER 43 OF 45 CAPLUS COPYRIGHT 1997 ACS
AN 1985:209178 CAPLUS
DN 102:209178
TI Drug targeting using monoclonal antibody-coated nanoparticles
AU Illum, Lisbeth; Jones, P. D. E.; Davis, S. S.
CS R. Dan. Sch. Pharm., Copenhagen, 2100, Den.

SO Microspheres Drug Ther.: Pharm., Immunol., Med. Aspects, [Pap.
Meet.] (1984), Meeting Date 1983, 353-63. Editor(s): Davis, Stanley
S. Publisher: Elsevier, Amsterdam, Neth.
CODEN: 53ORA3

DT Conference; General Review
LA English

L10 ANSWER 44 OF 45 SCISEARCH COPYRIGHT 1997 ISI (R)

AN 84:221949 SCISEARCH

GA The Genuine Article (R) Number: SM228

TI HUMAN-TUMOR GROWTH IN THE BRAIN AND SUBCUTANEOUS TISSUES

~~OF THE NUDE RAT - A NEW MODEL TO EVALUATE CHEMOTHERAPY AND~~
MONOCLONAL-ANTIBODY DELIVERY

AU NEUWELT E (Reprint); FRENKEL E; FARGON S; CARNEY D; MINNA J; BARNETT
P

CS OKLAHOMA STATE UNIV, PORTLAND, OR, 97201; NIH, BETHESDA, MD, 20205

CYA USA

SO PROCEEDINGS OF THE AMERICAN ASSOCIATION OF CANCER RESEARCH, (1984)
Vol. 25, No. MAR, pp. 255.

DT Conference; Journal

LA ENGLISH

REC No References

L10 ANSWER 45 OF 45 CAPLUS COPYRIGHT 1997 ACS

AN 1980:520304 CAPLUS

DN 93:120304

TI Use of antibodies for delivery of chemotherapeutic drugs

AU Sela, Michael; Hurwitz, Esther; Maron, Ruth

CS Weizmann Inst. Sci., Rehovot, Israel

SO Pontif. Acad. Sci. Scr. Varia (1979), 43, 481-517

CODEN: PASVAE; ISSN: 0377-9971

DT Journal

LA English

=> file wpids inpadoc

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.22

45.67

FILE 'WPIDS' ENTERED AT 14:46:26 ON 02 JAN 97

COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

FILE 'INPADOC' ENTERED AT 14:46:26 ON 02 JAN 97

COPYRIGHT 1997 (C) European Patent Office, Vienna (EPO)

=> s 12

L11 0 FILE WPIDS

L12 0 FILE INPADOC

TOTAL FOR ALL FILES

L13 0 L2

=> file japio

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.55

49.22

FILE 'JAPIO' ENTERED AT 14:47:14 ON 02 JAN 97

COPYRIGHT (C) 1997 Japanese Patent Office (JPO) and Japan Patent
Information Organization (Japio)

FILE LAST UPDATED: 04 DEC 96 <961204/UP>

=> s l2

6051 ANTIBODY

25272 DELIVERY

0 ANTIBODY DELIVERY

(ANTIBODY (W) DELIVERY)

2625 CANCER

2022 TUMOR

L14 0 ANTIBODY DELIVERY AND (CANCER OR TUMOR)

=> file home

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.95

50.17

FILE 'HOME' ENTERED AT 14:47:43 ON 02 JAN 97

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

50.32

SESSION WILL BE HELD FOR 60 MINUTES